Cytokine Production Regulating Th1 and Th2 Cytokines in Hemophagocytic Lymphohistiocytosis
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Hemophagocytic lymphohistiocytosis (HLH) is caused by the hyperactivation of T cells and macrophages. The clinical characteristics associated with this disease result from overproduction of Th1 cytokines including interferon-γ (IFN-γ), interleukin-2 (IL-2), and tumor necrosis factor-α (TNF-α). In this study, we analyzed the production of IL-12 and IL-4, which determine Th1 and Th2 response, respectively, and IL-10, which antagonizes Th1 cytokines, in 11 patients with HLH. IL-12 was detected in plasma in all patients (mean peak value, 30.0 ± 5.0 pg/mL), while IFN-γ was massively produced in nine patients (mean peak value, 79.2 ± 112.0 U/mL). IL-4 was not detected in any of the patients. Plasma IL10 levels were elevated in all patients (mean peak value, 2,698.0 ± 3,535.0 pg/mL). There was a positive correlation between the levels of IFN-γ and IL-10 (P < .01). The plasma concentrations of these cytokines were initially high, before decreasing after the acute phase. However, the decrease in IL-10 levels was slower than that of IFN-γ. Although the concentration of IL-12 was high at the acute phase, in some patients, a peak in the level was delayed until the chronic phase. Thus, in HLH, production of cytokines that promote development of Th1 cells appears to be predominant over that for Th2 cell development. Overproduction of IL-10 was also observed indicating that a mechanism suppressing hyperactivation of Th1 cells and monocytes/macrophages functions in patients with this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
de Waal Malefyt, R., Abrams, J., Bennett, B., Figdor, C. G., & de Vries, J. E. (1991) · The Journal of experimental medicine · doi:10.1084/jem.174.5.1209 · Cited by 3,762
Fiorentino, D. F., Bond, M. W., & Mosmann, T. R. (1989) · The Journal of experimental medicine · doi:10.1084/jem.170.6.2081 · Cited by 2,733
Trinchieri, G. (1995) · Annual Review of Immunology · doi:10.1146/annurev.iy.13.040195.001343 · Cited by 2,399
Moore, K. (1993) · Annual Review of Immunology · doi:10.1146/annurev.immunol.11.1.165 · Cited by 1,884
Lymphocyte responses and cytokines
Paul, W. E., & Seder, R. A. (1994) · Cell · doi:10.1016/0092-8674(94)90332-8 · Cited by 1,828
D'Andrea, A., Aste-Amezaga, M., Valiante, N. M., Ma, X., Kubin, M., & Trinchieri, G. (1993) · The Journal of experimental medicine · doi:10.1084/jem.178.3.1041 · Cited by 1,385
Homology of Cytokine Synthesis Inhibitory Factor (IL-10) to the Epstein-Barr Virus Gene BCRFI
Moore, K. W., Vieira, P., Fiorentino, D. F., Trounstine, M. L., Khan, T. A., & Mosmann, T. R. (1990) · Science · doi:10.1126/science.2161559 · Cited by 1,143
Nawroth, P. P., Handley, D. A., Esmon, C. T., & Stern, D. M. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.10.3460 · Cited by 582
Expression of Interleukin-10 Activity by Epstein-Barr Virus Protein BCRF1
Hsu, D.-H., Malefyt, R. D. W., Fiorentino, D. F., Dang, M.-N., Vieira, P., deVries, J., Spits, H., Mosmann, T. R., & Moore, K. W. (1990) · Science · doi:10.1126/science.2173142 · Cited by 535
Hypercytokinemia in familial hemophagocytic lymphohistiocytosis
Henter, J., Elinder, G., Soder, O., Hansson, M., Andersson, B., & Andersson, U. (1991) · Blood · doi:10.1182/blood.v78.11.2918.2918 · Cited by 505
Cited by
Teachey, D. T., Lacey, S. F., Shaw, P. A., Melenhorst, J. J., Maude, S. L., Frey, N., Pequignot, E., Gonzalez, V. E., Chen, F., Finklestein, J., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0040 · Cited by 1,102
CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Maude, S. L., Teachey, D. T., Porter, D. L., & Grupp, S. A. (2015) · Blood · doi:10.1182/blood-2014-12-580068 · Cited by 727
Familial and Acquired Hemophagocytic Lymphohistiocytosis
Janka, G. E. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-041610-134208 · Cited by 549
Hemophagocytic Syndromes and Infection
Fisman, D. N. (2000) · Emerging Infectious Diseases · doi:10.3201/eid0606.000608 · Cited by 548
Familial and acquired hemophagocytic lymphohistiocytosis
Janka, G. E. (2007) · European Journal of Pediatrics · doi:10.1007/s00431-006-0258-1 · Cited by 534
Hemophagocytic Lymphohistiocytosis
Al-Samkari, H., & Berliner, N. (2018) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043625 · Cited by 506
Pathogenesis of Macrophage Activation Syndrome and Potential for Cytokine- Directed Therapies
Schulert, G. S., & Grom, A. A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-061813-012806 · Cited by 402
Repeated TLR9 stimulation results in macrophage activation syndrome–like disease in mice
Behrens, E. M., Canna, S. W., Slade, K., Rao, S., Kreiger, P. A., Paessler, M., Kambayashi, T., & Koretzky, G. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci43157 · Cited by 392
“It is conceivable that differing IL-10 responses contribute to the variability of severity of MAS in human disease as well, since IL-10 is a cytokine that has been documented to be elevated in human patients (21).”
BackgroundHuman natural killer cell deficiencies and susceptibility to infection
Orange, J. S. (2002) · Microbes and Infection · doi:10.1016/s1286-4579(02)00038-2 · Cited by 338
Billiau, A. D., Roskams, T., Van Damme-Lombaerts, R., Matthys, P., & Wouters, C. (2005) · Blood · doi:10.1182/blood-2004-08-2997 · Cited by 308
Severe imbalance of IL-18/IL-18BP in patients with secondary hemophagocytic syndrome
Mazodier, K. (2005) · Blood · doi:10.1182/blood-2005-05-1980 · Cited by 290
de Jesus, A. A., Canna, S. W., Liu, Y., & Goldbach-Mansky, R. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112227 · Cited by 282
Imashuku, S. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(02)00117-8 · Cited by 271
Carter, S. J., Tattersall, R. S., & Ramanan, A. V. (2019) · Rheumatology · doi:10.1093/rheumatology/key006 · Cited by 259
Ahmed, A., Merrill, S. A., Alsawah, F., Bockenstedt, P., Campagnaro, E., Devata, S., Gitlin, S. D., Kaminski, M., Cusick, A., Phillips, T., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30156-5 · Cited by 256
Diagnostic Accuracy of a Specific Cytokine Pattern in Hemophagocytic Lymphohistiocytosis in Children
Xu, X.-J., Tang, Y.-M., Song, H., Yang, S.-L., Xu, W.-Q., Zhao, N., Shi, S.-W., Shen, H.-P., Mao, J.-Q., Zhang, L.-Y., et al. (2012) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2011.11.046 · Cited by 225
Pathogenesis of hemophagocytic syndrome (HPS)
Larroche, C., & Mouthon, L. (2004) · Autoimmunity Reviews · doi:10.1016/s1568-9972(03)00091-0 · Cited by 221
Ohadi, M., Lalloz, M. R. A., Sham, P., Zhao, J., Dearlove, A. M., Shiach, C., Kinsey, S., Rhodes, M., & Layton, D. M. (1999) · The American Journal of Human Genetics · doi:10.1086/302187 · Cited by 215
“Elevation of the concentrations of circulating cytokines, including g-interferon, interleukin-1 (IL-1), IL-6, and tumor necrosis factor a, is accompanied by high serum levels of soluble IL-2 receptor and CD8 (Komp et al. 1989; Henter et al. 1991b; Osugi et al. 1997).”
BackgroundBrisse, E., Wouters, C. H., & Matthys, P. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.10.001 · Cited by 204
“Indeed, elevated serum and tissue IFN-g levels have been detected in patients both with primary and secondary HLH [125,133–137] and currently, an anti-human IFN-g monoclonal antibody is in Phase I trial for patients with reactivated fHLH.”
BackgroundBrisse, E., Wouters, C. H., & Matthys, P. (2016) · British Journal of Haematology · doi:10.1111/bjh.14147 · Cited by 197
“Elevated IFN-c levels are often present in the sera of primary HLH patients, but not in all patients, and reported levels vary widely (Henter et al, 1991; Osugi et al, 1997; Nagasawa et al, 2008; Xu et al, 2012).”
BackgroundMaschalidi, S., Sepulveda, F. E., Garrigue, A., Fischer, A., & de Saint Basile, G. (2016) · Blood · doi:10.1182/blood-2016-02-700013 · Cited by 195
Molleran Lee, S., Villanueva, J., Sumegi, J., Zhang, K., Kogawa, K., Davis, J., & Filipovich, A. H. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.011528 · Cited by 188
Haemophagocytic syndromes in adults: current concepts and challenges ahead
Emmenegger, U., Schaer, D., Larroche, C., & Neftel, K. (2005) · Swiss Medical Weekly · doi:10.4414/smw.2005.10976 · Cited by 184
Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis
Bode, S. F., Lehmberg, K., Maul-Pavicic, A., Vraetz, T., Janka, G., Stadt, U., & Ehl, S. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3843 · Cited by 162
Nouveau, L., Buatois, V., Cons, L., Chatel, L., Pontini, G., Pleche, N., & Ferlin, W. G. (2021) · European Journal of Immunology · doi:10.1002/eji.202149181 · Cited by 25
Metadata
- Authors
- Osugi, Y., Hara, J., Tagawa, S., Takai, K., Hosoi, G., Matsuda, Y., Ohta, H., Fujisaki, H., Kobayashi, M., Sakata, N., Kawa-Ha, K., Okada, S., & Tawa, A.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1997-06-01
- Volume
- 89
- Issue
- 11
- Pages
- 4100-4103
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1848803438
- Cited by
- 366
- References
- 24
- FWCI
- 3.89
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.